Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07229157 · ClinicalTrials.gov registry record · Phase 1
Effect of Maridebart Cafraglutide on the Heart's Electrical Activity
A Phase 1 study of Obesity and Overweight, sponsored by Amgen.
- Active
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
- 2
- Study locations
NCT07229157 is a Phase 1 study of Obesity and Overweight that is active but no longer recruiting, run by Amgen. The registered enrollment target is 81 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07229157, a Phase 1 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in participants living with overweight or obesity.
Conditions Studied
Interventions
- DRUG Moxifloxacin
- DRUG Maridebart Cafraglutide
- DRUG Placebo for Maridebart Cafraglutide
- DRUG Placebo for Moxifloxacin
Study Locations (2)
Florida
- Fortrea Clinical Research Unit - Daytona Beach - Daytona Beach
Texas
- Fortrea Clinical Research Unit - Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2026-08-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07229157
The ClinicalTrials.gov registry entry for NCT07229157 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Moxifloxacin is the first listed.
NCT07229157 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT07229157 about?
NCT07229157 is a clinical study titled "Effect of Maridebart Cafraglutide on the Heart's Electrical Activity". The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in participants living with overweight or obesity.
What is the current status of trial NCT07229157?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2025-10-22. Estimated completion is 2026-08-26.
What conditions does trial NCT07229157 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT07229157?
The interventions under investigation include: Moxifloxacin (DRUG), Maridebart Cafraglutide (DRUG), Placebo for Maridebart Cafraglutide (DRUG), Placebo for Moxifloxacin (DRUG).
Who is sponsoring clinical trial NCT07229157?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07229157 being conducted?
This trial has 2 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.